Thomas Charles Merigan M.D.

Honors and Awards

• Endowed Thomas C and Joan M Merigan chair in Medicine, Stanford University (2008)
• Festschift with publication(J. of Inf. Dis. 162,Supp. 1,2006), Sponsored by former students (2004)
• George E. and Lucy Becker Professor of Medicine, Stanford University (!980-2006)
• One of "250 Most Highly Cited Scientists in Clinical Medicine over 20 years,1983-2001", Institute of Scientific Information (2004)
• Elected to Honorary Membership, International Society for Interferon and Cytokine Research (2001)

Graduate & Fellowship Program Affiliations

• Medicine

Current Research Interests

This laboratory is oriented toward strategies for prevention and treatment of chronic viral infections. The basic concept is that persistent viral infection or disease can be altered through the use of newer drugs or immunobiologics and through the study of host responses.

Publications

• Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, Workman C, Bloch M, Lalezari J, Becker S, Thornton L, Akil B, Khanlou H, Finlayson R, McFarlane R, Smith DE, Garsia R, Ma D, Law M, Murray JM, von Kalle C, Ely JA, Patino SM, Knop AE, Wong P, Todd AV, Haughton M, Fuery C, Macpherson JL, Symonds GP, Evans LA, Pond SM, Cooper DA. Nat Med. 2009; 15 (3): 285-92
• Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, Hirsch MS, Shafer RW, Robbins GK, Pollard RB. J Acquir Immune Defic Syndr. 2006; 42 (4): 426-34
• Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Motsinger AA, Ritchie MD, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, Johnson VA, Pollard RB, Merigan TC, Hirsch MS, Donahue JP, Kim RB, Haas DW. Pharmacogenet Genomics. 2006; 16 (11): 837-45
• "Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target. Martin P, Vickrey JF, Proteasa G, Jimenez YL, Wawrzak Z, Winters MA, Merigan TC, Kovari LC. Structure. 2005; 13 (12): 1887-95
• Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan TC, Kuritzkes DR. Clin Infect Dis. 2005; 41 (2): 236-42